# A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)

Source: https://onco.cc/trials/nct07011576/  
OnCo record `nct07011576` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of fruquintinib and fOLFIRI (5-FU, leucovorin, irinotecan) in colorectal cancer, run by SCRI Development Innovations, LLC, now recruiting.

## Summary

A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL) is a phase 2, interventional study registered as NCT07011576 by SCRI Development Innovations, LLC, with a registry enrolment figure of 60 participants, started 2025-09-29 and due to reach its primary completion in 2027-01. Interventions recorded: fruquintinib; FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin). Conditions listed: Colon Cancer; Rectal Cancer; Colorectal Cancer; Colorectal Cancer (CRC). Primary outcome: Progression-Free Survival (PFS) rate at 6 months. Colorectal eligibility wording from the registry: "* Confirmed mCRC ; histologically documented adenocarcinoma of the colon or rectum with at least one measurable lesion according to RECIST v1". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: FRUITFUL
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07011576
- Phase: 2
- Setting: A Phase II Study Investigating Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)
- Sponsor: SCRI Development Innovations, LLC
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT07011576: https://clinicaltrials.gov/study/NCT07011576

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/)
- drugs: [FOLFIRI (5-FU, leucovorin, irinotecan)](https://onco.cc/drugs/folfiri/), [Fruquintinib](https://onco.cc/drugs/fruquintinib/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07011576.json